Genentech, part of the Roche Group, has broken ground on its latest US manufacturing facility in Holly Springs, North Carolina. The development represents the company’s first major manufacturing facility on the East Coast. Covering 65,000 m², the manufacturing facility in USA will support production of metabolic medicines, including next-generation therapies for obesity.
Genentech’s North Carolina investment exceeds $700 million and forms a key component of Roche’s $50 billion commitment to expanding US manufacturing infrastructure and R&D. The facility is projected to create more than 1,900 jobs.
Roche Group CEO Thomas Schinecker stated: “I am proud to break ground on our new state-of-the-art manufacturing facility in North Carolina, which will support the production of our next-generation obesity treatments. This $700 million project is an integral part of our broader $50 billion commitment to further expand our already significant presence in the United States, building on our 120-year legacy of driving innovation and creating jobs across America. I am excited about the impact this facility will have on delivering life-changing medicines to patients in the US and around the world.”
Holly Springs was selected for its existing reputation as a biopharmaceutical hub of innovation, backed by a highly trained workforce, strong academic institutions, and access to other leading life science organizations.
The manufacturing facility in USA is scheduled for completion by 2029. Upon completion, it will boast advanced automation and digitalization. The 400,000 m² campus also allows room for expansion as the demand increases.
Built to produce high-volume, efficient, and sustainable production, the plant will significantly expand Roche’s global manufacturing capacity. It will also support supply chain resilience, complementing existing Roche sites in Europe and Switzerland, making it accessible for patients worldwide.
